Inhibitory effect of rapamycin on stromal cell-derived factor-1 expression in intimal hyperplasia

Abstract

Abstract: AIM: To investigate the anti-restenosis molecular mechanism of rapamycin.METHODS: The animal models of rat carotid artery intimal hyperplasia was established with Balloon injury.Rats were randomized divided into two groups: baseline group (n=10) and treatment group (n=10 rapamycin, 25 mg/kg). HE staining was used to observe vascular lesions.Immunochistochemistry staining was used to detect the expression of SDF-1 in lesions.The migration of smooth muscle cells induced by stromal cell-derived factor 1 (SDF-1) was observed with transwell.RESULTS: Intimal hyperplasia was obviously induced by balloon injury.SDF-1 highly expressed in lesions and rapamycin significantly reduced the expression of SDF-1 in intimal hyperplasia.SDF-1 induced the migration of smooth muscle cells with concentration-dependent manner.CONCLUSION: Rapamycin may inhibit vascular restenosis by inhibiting the migration of smooth muscle cells induced by SDF-1.

Key words: rapamycin, intimal hyperplasia, stromal cell-derived factor-1(SDF-1), balloon injury

CLC Number:

R965.1

LEI Jian-jun, XIA Yi-ping, HU Yan, WANG Zuo, LONG Guang, WEI Dang-heng. Inhibitory effect of rapamycin on stromal cell-derived factor-1 expression in intimal hyperplasia[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(6): 644-647.

References

[1] 王祥, 冯义柏, 曹林生, 等. 冠状动脉内支架置入术在冠心病治疗中的应用[J]. 临床心血管病杂志, 2002, 18(5): 202-203.
[2] 王传平, 朱敬松, 宋静, 等. PTCA 术后再狭窄不同介入方法治疗效果观察[J]. 医药论坛杂志, 2006, 27 (3): 50-51.
[3] 吴绍熙. 大环内醋类免疫抑制剂研究进展[J]. 中国新药杂志, 2001, 10(8): 566.
[4] Oberhoff M, Herdeg C, Baumbach A, et al. Stent-based antirestenotic coatings (Sirolimus Paclitaxel)[J]. Catheter Cardiovasc Interv, 2002, 55(3): 404-408.
[5] Moses JW, LeonMB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery[J]. N Engl Med, 2003, 349(14): 1307-1323.
[6] 苗志林, 曾定尹. 雷帕霉素防治动脉成形术后血管再狭窄的研究进展[J]. 中华心血管病杂志, 2004, 32(1): 85-86.
[7] Gleichmann M, Gillen C, Czardybon M, et al. Cloning and characterization of SDF-1gamma, a novel SDF-1 chemokine transcript with developmentally regulated expression in the nervous system[J]. Eur J Neuro Sci, 2000, 12 (6): 1857-1866.
[8] 王承艳, 苗振川, 丰美福. 基质细胞衍生因子SDF-1及其受体CXCR4 在造血干祖细胞动员及归巢过程中的作用[J]. 中国实验血液学杂志, 2004, 12 (1): 115-119.
[9] 吴孟津, 危当恒, 王贵学, 等. 低剪切应力促进基质细胞衍生因子1 在动脉粥样硬化斑块中表达[J]. 中国动脉硬化杂志, 2006, 14(12): 1028-1030.
[10] Lǜbbe J, Sorg O, Malé PJ, et al. Sirolimus-induced inflammatory papules with acquired reactive perforating collagenosis[J]. Dermatology, 2008, 216(3): 239-242.
[11] Miyazawa A, Tsujino I, Ako J, et al. Characterization of late incomplete stent apposition: a comparison among baremetal stents, intracoronary radiation and sirolimus-eluting stents[J]. Invasive Cardiol, 2007, 19(12): 515-518.
[12] Hausleiter J, Kastrati A, Mehilli J, et al. OSIRIS Investigators. Randomized, double-blind, placebo-controlled trial of oralsirolimus for restenosis prevention in patients with instent restenosis: the Oral Sirolimus to Inhibit Recurrent Instent Stenosis (OSIRIS) trial[J]. Circulation, 2004, 110 (7): 790-795.
[13] Rodriguez AE, Granada JF, Rodriguez AM, et al. ORAR II Investigators. Oral rapamycin after coronary bare-metal stent implantation to prevent restenosis:the prospective, randomized oral rapamycin in Argentina (ORAR II) study [J]. J Am Coll Cardio, 2006, 47(8): 1522-1529.
[14] Abi Younes S, Sauty A, Mach F, et al. The stromal cellderived factor-1 chemokine is a potent platelet agonist highly expressed in atherosclerotic plaques[J]. Circ Res, 2000, 86(2): 131-138.
[15] Schober A, Zernecke A, Liehn EA, et al. Crucial role of the CCL2 CCR2 axis in neointimal hyperplasia after arterial injury in hyperlipidemic mice involves early monocyte recruitment and CCL2 presentation on platelets[J]. Circ Res, 2004, 95(11): 1125-1133.
[16] 陈图刚, 陈君柱, 王兴祥. 雷帕霉素对内皮祖细胞数量与功能的影响[J]. 解放军医学杂志, 2006, 31(4): 316-318.